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Abstract 
Herbal supplements are used increasingly in both developed and undeveloped countries for 
purposes of prevention, delaying onset, decreasing overall severity, and potential reversal of 
mental illness. The purpose of this overview is to present the latest empirical findings regarding 
the efficacy of various herbal and nutraceutical supplements in the prevention, treatment, and 
delaying onset of symptomology in relation to schizophrenia and other schizoaffective disorders, 
as well as further to explore their potential role in the future of psychiatry and related health 
practices.  The supplements and their efficacy examined in this literature overview are Omega-3 
fatty acids, Curcumin, Folic Acid, B12, B6, vitamin D, N-acetylcysteine, SAM-e, Bocopa 
Monniera, Ginkgo Biloba, Iron, Glycine, (−)–Stepholidine, Yokukansan, Orengadoku, and Ficus 
Platyphylla, 
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Herbal and nutraceutical supplements are being studied for their ef-fects on symptoms of mental illness. Reductions in mental illness 
symptomology have been found with use of particular phytochemicals, 
adaptogenic herbs, essential fatty acids, and traditional Chinese and Ama-
zonian medicine. Mussarat et al. (2014) state that of the reported 422,000 
flowering plants that have been reported around the world, over 50,000 
are used medicinally. Further, Mussarat et al. (2014) suggest that 80% of 
the population of developing countries and 60% of the world population 
rely on traditional medicine, and over 4.5 billion people within developing 
countries rely on medicinal plants for their health maintenance. This data 
presented by Mussarat et al. (2014) displays the wide-reaching breadth of 
indigenous medicine for traditional health practices and has great implica-
tions for the number of psychiatric issues that can be addressed with the 
phytochemical constituents of these botanicals. Particularly, schizophre-
nia and schizoaffective disorders have been indicated by the literature to 
benefit largely from the supplementation of herbs and nutraceuticals. Chen 
and Hui (2012) note schizophrenia to be a severe psychiatric disorder that 
negatively impacts a wide-range of cognitive functions such as executive 
functioning, memory and attention (p. 1166-72). Schizophrenia is char-
acterized by negative symptoms (such as emotional blunting and apathy), 
positive symptoms (hallucinations and delusions), and mild to severe 
impairment of cognition.
The ideal treatment would eliminate these negative, positive, and 
cognitive symptoms. This is important to note, as Brown and Roffman 
(2014) state that while antipsychotic medications can often aid in reducing 
positive symptoms, these pharmaceuticals produce little to no response in 
regard to negative symptoms and cognitive impairment (p. 611-22). In so 
far as the etiology of schizophrenia is concerned, it is generally accepted 
that it is multifactorial, with a particular combination of environmental 
circumstances and biological predisposition playing the major role. Mir-
sky and Duncan (1986) note, however, that there is much disagreement 
with respect to the weighting of environmental to biological factors in the 
etiology of schizophrenia (p. 291-319). Mayer et al. (2011) suggest that 
researchers are still not positive as to a precise prognosis for those deal-
ing with schizophrenia, but there are certain factors posited negatively 
to affect prognosis, such as: lack of social support, indolent onset, poor 
insight and presence of negative symptoms (p. 140-41). While there are 
many typical and atypical antipsychotic medications for the treatment of 
schizophrenia, Doruk, Uzun, and Ozsahin (2008) report that many patients 
show little to no response to these interventions—necessitating an urgent 
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need for alternative treatments of high efficacy and few adverse effects (p. 
223-27).  Additionally, research has shown that in individuals with schizo-
phrenia, consumption of essential amino acids, vitamins, and nutritional 
building blocks to raise levels of neuroprotective chemicals such as endog-
enous glutathione (by way of precursors like N-acetylcysteine and Alpha 
Lipoic Acid) can decrease cortical inflammation and help maximize the 
body’s innate compensatory homeostatic healing mechanisms to deal more 
effectively with states of psychosis. Various studies have displayed a rep-
ertoire of supplements, stand-alone or adjunct with traditional pharmaceu-
tical approaches, to be as effective as pharmaceutical treatment, and have 
fewer side-effects, and some have even been found to make reparations to 
vital physiological and psychological operations—and be ceased—without 
relapse or necessitation of alternative interventions. 
Literature Review
Omega 3 fatty acids
Omega-3 fatty acids, or n-3 polyunsaturated fatty acids (PUFAs), are 
amassing significant attention in the literature on alternative avenues for 
the treatment of psychotic disorders. Omega-3 PUFAs supply a wide range 
of neurochemical activities via their modulation of the reuptake, degrada-
tion, synthesis and receptor binding actions of noradrenaline, dopamine 
and serotonin. Omega-3s also possess anti-inflammatory and anti-apoptot-
ic effects in addition to their significant activity in increasing neurogenesis 
and cell membrane fluidity. According to one study led by Amminger 
(2015), it has been found that intervention with omega-3 fatty acids may 
reduce the risk of pathogenesis with respect to psychotic disorders as 
well as a reduced risk of psychiatric morbidity. This study noted that the 
individuals in the omega-3 group no longer displayed severe functional 
impairment, nor did they experience dramatic psychotic symptoms upon 
a 6.7 year follow-up of this randomized, double-blind, placebo-controlled 
trial (Amminger, Schäfer, Schlögelhofer, Klier, & Mcgorry, 2015). Re-
search indicates that many developed countries, such as America, are 
deficient in essential vitamins, minerals, and omega-3 fatty acids. Those 
suffering from mental illness are exceptionally deficient in Omega-3s. 
Research also posits the brains of schizophrenic persons to have profound 
abnormalities in myelin sheaths and oligodendrocytes, and suggests that 
Omega-3 fatty acids are essential for the reparation and maintenance of 
these. The eicosapentaenoic acid (EPA) found in Omega-3s is noted to 
aid in the maintenance of a balanced mood and improving blood circula-
tion. Two grams of EPA adjunct with one’s normal antipsychotic regimen 
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effectively decreased overall symptoms of schizophrenia in those suffering 
(Ibrahim & El-Sayed, 2013).
Curcumin and Glycine
Curcumin, a common household spice, is a polyphenol with an active 
medicinal component being turmeric, or curcuma longa. Studies show 
that it possesses significant antidepressant properties in both rodents and 
humans without adverse effects. A 6 week placebo-controlled study found 
that chronic supplementation of curcumin (1,000 mg daily) produced 
significant antidepressant behavioral responses in depressed participants as 
measured by reduction of 17-item Hamilton Depression Rating Scale and 
Montgomery-Asberg Depression Rating Scale scores. Furthermore, this 
same study found curcumin to decrease levels of inflammatory cytokines 
interleukin 1β and tumor necrosis factor α level, and it was found to in-
crease brain-derived neurotropic factor (BDNF) levels in plasma concen-
trations while decreasing concentrations of salivary cortisol as compared 
to placebo (Lopresti, Maes, Maker, Hood, & Drummond, 2014). Another 
study, carried out by Hishikawa et al. (2012), examined three patients with 
Alzheimer’s disease (AD) and found curcumin to facilitate the recovery 
of cognitive decline and Psychological Symptoms of Dementia (BPSD). 
After 12 weeks of treatment there was a significant decrease in the acuity 
of symptoms and the burden on caregivers. Within one year of treatment 
with curcumin, participants with AD began to recognize their families 
once again (p. 499-504). Curcumin has been found to exhibit antioxidant, 
anti-inflammatory, and anti-cancer properties. Additionally, it is known to 
act as a neuroprotective agent in neurological disorders and can cross the 
blood-brain barrier with significant bioavailability. Multiple studies have 
found it effective in the amelioration of motor symptoms in Parkinson’s 
disease as well (Mythri & Bharath, 2012). Furthermore, in addition to 
its neuroprotective properties, it has been found to modulate oxidative-
stress induced apoptosis and neuroinflammation (Rinwa, Kumar, & Garg, 
2013). Lastly, a study found that curcumin extract was able to significantly 
restore depleted glutathione levels and recover oxidative damage after 72-
hour sleep deprivation in mice (Kumar & Singh, 2008). 
Curcumin extract was found to lessen some of the serious side effects 
associated with use of neuroleptics to schizophrenic patients (Trebatická 
& Ďuračková, 2015). Curcumin was able to reverse oxidative damage 
induced by haloperidol. Chronic administration of haloperidol was found 
to decrease the turnover of dopamine, serotonin and norepinephrine, 
which was dose-dependently reversed through utilization of curcumin. 
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The results of this study suggest curcumin as a potential aid in orofacial 
dyskinesia, a hyperkinetic disorder of high-incidence and unfortunate 
irreversibility during the treatment of schizophrenia with haloperidol 
(Bishnoi, Chopra, & Kulkarni, 2008). High doses of glycine, an endog-
enously produced amino acid, have been found effective at 30 grams per 
day to reduce social withdrawal, emotional flatness, and states of apathy in 
schizophrenia—these being symptoms usually unresponsive to traditional 
antipsychotic medication. Additionally, clinical trials revealed that glycine 
given at 60 grams per day could be administered to schizophrenic patients 
with no adverse effects, as well as a twofold increase of glycine levels in 
the cerebrospinal fluid (CSF) (Ibrahim & El-Sayed, 2013).
B vitamins
The B vitamins folic acid, B12, and B6 play a pertinent role in neuro-
nal function. Deficiencies in these have been indicated in increased risk 
of psychiatric disease and dementia (Mitchell, Conus, & Kaput, 2014). 
Deficiencies in Cobalamin, an important nutrient that is not synthesized 
endogenously and supplied in non-vegetarian diets, has been reported with 
a range of psychiatric disorders, and a case-report found dietary cobalamin 
deficiency to present solely as a schizoaffective disorder without neuro-
logical manifestations (Dhananjaya, Manjunatha, Manjunatha, & Kumar, 
2015). The most common of psychiatric symptoms found to be reported in 
the literature on vitamin B12 deficiencies are depression, mania, impaired 
cognition, dementia, delirium, psychotic symptoms, OCD, and states of 
confusion. Vitamin B12 deficiency is indicated to be causative of sub-
acute combined degeneration (SCD) where there is a demyelination of the 
lateral and dorsal spinal cord. Symptoms of SCD manifest in the way of 
psychosis, dementia, and severe depression. Nevertheless, these symptoms 
can be prevented with B12 supplementation (Naik & Dsouza, 2015). Even 
further, deficiencies in B12 have been linked to a proliferation of vascular 
risk factors and increase homocysteine and the load of cognitive decline 
in neuropsychiatric illnesses (Issac, Soundarya, Christopher, & Chandra, 
2015).  B Vitamins and a broad-spectrum multivitamin were also found to 
significantly improve levels of stress and anxiety associated with natural 
disasters while achieving a large effect size in the study (Kaplan, Ruck-
lidge, Romijn, & Dolph, 2015).  Vitamin B6 was found to reduce extra-
pyramidal side-effects of typical antipsychotics. The same study found 
N-acetylcysteine (NAC) to be effective against the negative symptoms of 
schizophrenia, as well as akathisia and abnormal movements in schizo-
phrenia (Himmerich & Erbguth, 2014). 
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N-acetylcysteine (NAC)
NAC has proven to hold a significant role in the aid of pathophysio-
logical processes associated with psychiatric and neurological disorders. A 
systemic review by Deepmala et al. (2015) has found favorable evidence 
regarding NAC supplementation for disorders such as autism, Alzheimer’s 
disease, bipolar disorder, depression, OCD tendencies, and schizophre-
nia. NAC’s action of lowering levels of glutamate is indicated to be a 
key factor in its role of the amelioration of OCD and various grooming 
disorders (Racz, Sweet, & Sohoni, 2015). Another study found that in 
individuals with chronic schizophrenia (SZ), adjunctive NAC—when 
compared to placebo—has therapeutic potential for overall functioning 
and a decrease in positive symptoms of schizophrenia (Rapado-Castro et 
al., 2015). Several lines of research and empirical evidence have indicated 
that a large component of the pathogenesis of schizophrenia is a deficit 
in brain glutathione (GSH) levels by result of impaired GSH synthesis. A 
study supplemented individuals suffering from schizophrenia with a GSH 
precursor, NAC, which significantly reduced clinical severity and negative 
symptoms. This same study concluded that polyphenol, curcumin, and the 
flavonoid quercetin were able significantly to increase levels of GSH and, 
in turn, reduce the overall clinical severity of schizoaffective disorders 
(Lavoie et al., 2009).
Vitamin D (VD) and Iron
Seven research studies examining patients with psychosis all indicated 
insufficient levels of vitamin D (VD). A mini-analyses of these studies 
found that there was a medium-level effect size for VD in schizophrenia as 
opposed to the healthy controls, in addition to a trend for overall lower VD 
levels in comparison to other forms of psychosis (Belvederi et al., 2013). 
A study examining a Finnish cohort group of over 9,000 people examined 
supplementation of vitamin D at levels of 2,000 IU per day in the first year 
of life and noted a 77% decrease in the risk of developing schizophrenia 
in males compared to those receiving less than 2,000 IU per day. It is 
hypothesized by the researchers that vitamin D supplementation early in 
life is pertinent in pro-differentiating signals in the critical periods of brain 
development, as well as recovery from brain damage after injury (Brown 
& Roffman, 2014). There are many other vitamin and mineral deficien-
cies that are posited to play a role in the pathogenesis of schizophrenia. 
Research has suggested maternal iron-deficiency to induce fetal hypoxia 
as a result of the high oxygen demand on the part of the growing fetus. 
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Fetal hypoxia has a plethora of research showing consistent implications 
as a risk factor for the development of schizophrenia; specifically, it may 
predispose the child to an expression of schizophrenia in adulthood (Ibra-
him & El-Sayed, 2013).
S-Adenosyl methionine (SAM-E)
An increasingly common over-the-counter supplement as an aid for the 
treatment of depression, SAM-E, was found (over a randomly-assigned, 
8 week, placebo-controlled, and double-blind fashion study) significantly 
to reduce symptoms of psychosis such as aggressive behavior. Strous et 
al. (2009) report that SAM-E’s predominant function is as a methyl group 
donor for catecholamines, membrane phospholipids, fatty acids, choline 
carnitine, creatinine, nucleic acids, and porphyrins. A crucial function 
of SAM-E, as noted by Strous et al. (2009), is myelination of certain 
phospholipids to promote fluidity and microviscosity of cell membranes. 
Furthermore, it was posited that the metabolism of SAM-E is crucial for 
the maintenance of myelin—myelin being essential for facilitating effi-
cient signal conduction between neurons, among many other physiological 
roles. As for SAM-E’s relationship to schizophrenia, Strous et al. (2009) 
hypothesized that by way of its methyl donor activity, SAM-E would af-
fect catechol-O-methyltransferase (COMT) enzyme expression, in turn 
diminishing aggressive behavior in individuals with schizophrenia who 
possess the low activity COMT polymorphism—possession of which is 
noted to be somewhat common. SAM-E was found to improve overall 
quality of life, and in females the research has shown it to improve depres-
sive symptoms as well (Strous et al., 2009). 
Bacopa Monniera
The herbal extract of Bacopa Monniera was found to have significant 
neuroleptic effects with a reduction of dopamine concentration in the 
frontal cortex. There was a significant reduction of conditioned avoidance 
response and reduction of amphetamine-induced stereotype. The results 
of this study reveal that Bacopa Monniera may hold significant potential 
for the amelioration of the positive symptoms of schizophrenia (Jash & 
Chowdary, 2014). The herb Ficus Platyphylla (FP) was shown to have 
neuroleptic-like properties and significantly reduce locomotor activity. 
The study was able to reverse an apomorphine-induced prepulse inhibi-
tion deficit and hyperactivity by utilizing a co-administration of clozapine 
or FP. Even further, FP was able to inhibit the retrieval of a conditioned 
avoidance reaction in individuals with schizophrenia (Chindo et al, 2015). 
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Ginkgo Biloba (Egb)
Ginkgo Biloba (Egb) extract has been suggested to possess anti-oxi-
dant and anti-inflammatory mechanisms of action. Furthermore, Egb has 
been shown to increase cerebral blood flow and possess antiplatelet effects 
that have been attributed to terpene and flavone lactones as well (Dia-
mond & Bailey, 2013). Egb is indicated by the literature to be a signifi-
cant adjunct aid to the pharmacological treatment of schizophrenia, as its 
primary pharmacodynamics component is an antioxidant. Egb is believed 
to provide a favorable adjunctive treatment for schizophrenia with clo-
zapine, as it significantly decreases the negative symptoms of individuals 
with schizophrenia. The researchers suggest this may be due to the anti-
oxidant action of Egb or the effect it holds on the serotonergic pathway. 
Even further, Egb administration displayed the capability of normalizing 
levels of serotonin in the brain (Doruk, Uzun, & Ozsahin, 2008). Another 
study examining the adjunctive impact of Egb treatment with a prescrip-
tion antipsychotic found a statistically significant moderate improvement 
with respect to the total and negative symptoms of schizophrenia. The 
research selection criteria involved 466 cases on ginkgo with 362 cases on 
placebo—utilizing the Scale for the Assessment of Negative Symptoms 
(SANS), the Scale for the Assessment of Positive Symptoms (SAPS), the 
Brief Psychiatric Rating Scale (BPRS) to measure the positive, negative 
and total symptoms. This same study explored the role of antioxidants in 
schizophrenia’s pathogenesis, indicating oxidative damage may hold a 
causative role in the progression of schizophrenia (Singh, Singh, & Chan, 
2010).  
Traditional Chinese Medicine (CM)
In 2011, research found that concomitant use of antipsychotics and 
traditional Chinese medicine (CM) in patients with schizophrenia held a 
significantly higher chance of improved outcomes than those who solely 
used prescription antipsychotics—61.1% in the adjunctive treatment group 
with CM versus 34.3% improvement rates in those only utilizing antipsy-
chotics, indicating a potential herb-drug interaction (Z. Zhang et al., 2011). 
A double-blind, placebo-controlled clinical trial looking to improve cogni-
tive impairments in patients with schizophrenia found that treatments were 
generally well tolerated, with no reported unwanted side-effects (Z. Chen 
et al., 2008).
(−)–Stepholidine (SPD)
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An active ingredient of the Chinese herb Stephania, known as (−)–Ste-
pholidine (SPD), is the first compound found to hold a dual function as a 
dopamine D1 receptor agonist and a D2 antagonist (Fu et al., 2007). This 
has led to an increase in research being done on the potential antipsychotic 
properties of SPD. One study investigating these properties in two animal 
models for schizophrenia found antipsychotic-like effects in the prepulse 
inhibition paradigm and in the PAW test. Additionally, the PAW test sug-
gested SPD to be of atypical character with a relatively small potency for 
inducing extrapyramidal side-effects (Ellenbroek, Zhang, & Jin, 2006). 
It is suggested that schizophrenia is associated with excessive stimula-
tion of striatal D2 dopamine receptors, too little stimulation of the medial 
prefrontal cortex D1 dopamine receptors, and neuronal apoptosis. With 
that said, research has found SPD to hold anti-apoptotic mechanisms in 
addition to its functions with respect to the D1 and D2 receptors, making 
it a promising candidate to hold therapeutic action against schizophrenia 
(L. Zhang, Zhou, & Xiang, 2005). In the way of adjunct treatment, co-
administration of SPD with a typical antipsychotic drug was found sig-
nificantly to enhance the therapeutic effects as well as markedly reduce 
conditions induced by typical antipsychotics such as tardive dyskinesia. 
SPD as a stand-alone treatment displayed therapeutic value without sig-
nificant extrapyramidal side-effects, and it was able to reduce the negative 
symptoms of schizophrenia. This was confirmed utilizing animal models 
of schizophrenia wherein SPD improved cognitive function, social inter-
action, and inhibited hyperactivity in schizophrenic animals (Mo, Guo, & 
Yang, 2007).
Yokukansan (TJ-54)
The medicinal herb Yokukansan (TJ-54) was found by Miyaoka et al. 
(2013) to induce displays of highly significant improvement with respect 
to all measures of psychotic symptomology in the patients involved in the 
clinical research. Miyaoka et al. (2013) state that the hooks of TJ-54 con-
tain indol and oxyindole alkaloids that protect against glutamate-induced 
neuronal death. Angelica radix, another component of TJ-54, is known for 
the effects it has on particular serotonin receptors. Considering that previ-
ous research has displayed schizophrenia to commonly present dysfunc-
tion of serotonin, glutamate, and dopamine receptors, TJ-54 seems to have 
the pharmacological properties necessary to be a viable treatment option 
for individuals with schizophrenia. The research by Miyaoka et al. (2013) 
showed that TJ-54 was very well-tolerated by the patients, and there were 
no observed adverse effects. This study concluded that TJ-54 seems to be 
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an efficacious alternative treatment for very-late-onset schizophrenia and 
related forms of psychosis (Miyaoka et al., 2013b). A double-blind, place-
bo-controlled, randomized trial examining the effects of TJ-54 on treat-
ment-resistant schizophrenia found the TJ-54 group to display statistically 
significant improvements in the PANSS excitement/hostility measures, 
with no significant side-effects reported (Miyaoka et al., 2013a). 
Orengedoku
Another study, adding to TJ-54 the medicinal supplement orengedoku, 
resulted in the same efficacy as the atypical antipsychotic aripiprazole in 
the management of aggressiveness and impulsions to aggressive behavior, 
as well as improvement of tardive dystonia (by 80%). With reductions 
in irritability, impulsivity, and aggression, these two supplements taken 
together may be a combination worth exploring further. The individual in 
whom the aggressive impulses were measured had been on olanzapine, 
which was unsuccessful in abating his anger and even induced somno-
lence, unlike the combination of TJ-54 and orengedoku, which improved 
his symptoms (Okamoto et al., 2013). 
Lonchocarpus cyanescens (LC)
A medicinal plant known as lonchocarpus cyanescens (LC) has been 
used in traditional medicine for the treatment of psychotic disorders, and 
the research on its antipsychotic-like efficacy explored why this may be 
such a potentially vital addition in the amelioration of psychotic disorders. 
A preliminary phytochemical screening of LC suggested the presence of 
constituents with anti-psychotic properties, such as: alkaloids, cardiac 
glycosides, cyanogenetic glycosides, flavonoids, steroids, saponins, an-
thraquinones, and tannins. Ethanolic and aqueous extracts of LC were 
able to suppress stereotyped behavior induced by amphetamines in rats 
and further produced a significant reduction in spontaneous motor ac-
tivity in the open field test. The research is indicative of LC containing 
phytochemically-active antipsychotic constituents that may be efficacious 
in the management of varying forms of psychoses (Sonibare, Umukoro, & 
Shonibare, 2012).
Discussion
There is no blanket strategy for therapeutic approaches to schizophre-
nia, but a significant number of studies have indicated the clinical potential 
of adjunctive therapies with antipsychotics (or stand-alone) utilizing sup-
plementation of antioxidants, B vitamins, anti-inflammatory, and neuro-
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protective nutrients, as well as dietary-restrictive practices (Arroll, Wilder 
& Neil, 2014). It is very important to note that due to lack of regulation by 
the FDA, using herbal and nutraceutical supplementation can have contra-
indications with any preexisting treatment regimen one may be prescribed. 
Furthermore, using these supplements in place of one’s prescribed treat-
ment regimen without consulting one’s doctor can be very dangerous and 
is not recommended. 
While much of the research regarding the aforementioned supplements 
indicates there may be less risk associated with their use when compared 
to traditional antipsychotics, one should still consult their mental health 
practitioner or doctor before making any adjustments to one’s treatment 
protocol. Moreover, dosages for a majority of herbal supplements have 
not been standardized, so one should proceed with caution and only after 
speaking with a mental health professional. These herbs and nutraceuti-
cals can play a vital role for many people in recovery from and the stav-
ing off mental illness, especially considering the high rate of nutritional 
deficiencies in the population at large. Research by Fryar-Williams and 
Strobel (2015) indicates that schizophrenia and schizoaffective disorders 
are significantly correlated with nutritional and biochemical biomarkers 
identified as deficiencies in vitamins D, B6, and folate, as well as oxida-
tive stress. Brown and Roffman (2014) note that specific vitamin levels 
at various critical periods of prenatal development play a very crucial 
role in determining whether or not an individual will develop schizo-
phrenia. Doruk et al. (2008) hypothesize that excessive free radicals and 
their consequent damage play a significant role in the symptomology of 
schizophrenia. Doruk et al. (2008) also suggest that these highly destruc-
tive and active free radicals are products of the excess metabolism for the 
neurotransmitter dopamine and can cause membrane damage in addition 
to overall cognitive dysfunction. Disturbances in amino acid metabolism 
have been implicated in the pathogenesis of schizophrenia as well.
Recently, however, some research is beginning to view schizophrenia 
as a neurodevelopmental disorder, being a product of our experiences that 
took place in the first years of our life, our prime developmental period 
(Ibrahim & El-sayed, 2013).  Russinova, Wewiorski, and Cash (2002) 
examined the use of alternative health practices in individuals with severe 
mental illness and noted that herbs and nutritional supplements were the 
second highest methods used in the treatment of schizophrenia—the first 
being spiritual practice—when compared to yoga, guided imagery, chi-
ropractic, and massage therapy. It is important to highlight the results of 
this research by Russinova et al. (2002), as supplementation and pharma-
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ceuticals are not the end-all approach to the amelioration of the symptoms 
of schizophrenia—psychosocial and spiritual domains of treatment have 
displayed much clinical significance. A study by Mohr, Brandt, Borras, 
Gilliéron, & Huguelet (2006) revealed that spiritual practice was able to 
instill hope, meaning and purpose in 71% of 115 individuals suffering 
from schizophrenia. Even further, spirituality decreased psychotic and 
general symptoms in 54% of the sample size, increased social integration 
in 28%, and decreased the risk of suicide attempts in 33% of the individu-
als in this study. Going back to the research by Russinova et al. (2002), 
herbs and nutraceuticals were able to provide a wide array of significant 
improvements in those with schizophrenia, such as increased energy 
levels, enhanced overall perception of health, and reduced levels of pain. 
Furthermore, these supplements were generally found useful in increasing 
emotional stability and alleviating anxiety, in addition to decreasing social 
isolation and being causative of a perceived overall increase in sense of 
well-being. 
Stepping aside from the herbs and nutraceuticals empirically suggested 
to be therapeutic candidates for schizophrenia and other psychiatric ill-
ness, there are thousands of potential herbal remedies that have yet to be 
discovered and properly researched. The Amazon and the people therein 
utilize many psychoactive plants to alleviate the symptoms of—and po-
tentially cure—a variety of psychiatric conditions. Research carried out 
by Mckenna, Ruiz, Hoye, Roth, and Shoemaker (2010) examined 128 
Amazonian ethnobotanical compounds that were collected in the Loreto 
province of Iquitos, Peru. From these 128 plant species, 228 fractions were 
screened using 31 radioreceptor assays and a subset were screened utiliz-
ing functional assays at adrenergic, muscarinic, and serotonin receptors. 
Mckenna et al. (2010) found that 40% of the botanical samples possessed 
potential therapeutic CNS activity for the diminution of cognitive deficits 
associated with schizophrenia and dementia via significant inhibition of 
radioligand binding activity and both antagonistic and agonistic functions 
with respect to muscarinic, adrenergic, and serotonergic receptors in vitro.
This study is only skimming the surface with respect to potentially 
clinically significant herbal compounds. More extensive research with 
these compounds, and all other botanicals with promising CNS activ-
ity, needs to be carried forth to expand our ethnomedicinal catalogue and 
possibly discover novel phytochemical properties with therapeutic and 
clinical potential. Similar to the promising botanicals within the Amazon, 
Mussarat et al. (2014) examined the traditional uses of plants of the Dera 
Ismail Khan District in north-west Pakistan, indicating this area to be one 
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of the country’s richest in terms of biodiversity while simultaneously hav-
ing had very few ethnobotanical studies carried out within its parameters. 
Going forward, there should come a time where it is widely acknowledged 
that the current pharmacologic treatment repertoire is simply lacking in 
pertinent areas where treatments are increasingly necessitated by growing 
rates of chronic illness and other health crises. These unexplored lands rich 
in biodiversity, but neglected by empirical research, should be preserved 
and explored in the reasonable hope that the unexamined botanical spe-
cies therein may fill the void of viable treatment options made manifestly 
apparent by the growing rates of those suffering without cure The earth 
is by no means lacking in medicine; however, funding for ethnobotanical 
research is a different story. 
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